The investigators assembled in the DF/HCC Myeloma SPORE have a substantial long-term record in mentorship and development of junior faculty working in translational myeloma research. The goal of the Career Development Program of our Myeloma SPORE is to build upon this record and establish a formal process for the identification, selection, funding, and mentoring of individuals pursuing careers in the study of the basic and clinical aspects of myeloma. These awards will facilitate the development of physicians, physician scientists, clinical investigators, and scientists in training within the Myeloma SPORE Program towards faculty status. Thus, candidates will be junior faculty or fellows and postdoctoral fellows within the various training programs across DF/HCC and participating institution. Our Career Development Program has been extremely successful in the previous funding period, with three investigators now having independent funding and eight have attained independent faculty positions and promotions as a direct result of this Program. It is our goal to continue to attract, mentor, and assure the success of several candidates within the timeframe of this SPORE. Success will be defined as the development of physician/scientists in training towards careers as independent investigators.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA100707-11A1
Application #
8607278
Study Section
Special Emphasis Panel (ZCA1-RPRB-0 (O1))
Project Start
2003-09-01
Project End
2018-08-31
Budget Start
2013-09-18
Budget End
2014-08-31
Support Year
11
Fiscal Year
2013
Total Cost
$150,072
Indirect Cost
$58,444
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Das, D Sharma; Ray, A; Das, A et al. (2016) A novel hypoxia-selective epigenetic agent RRx-001 triggers apoptosis and overcomes drug resistance in multiple myeloma cells. Leukemia 30:2187-2197
Tagde, Ashujit; Rajabi, Hasan; Stroopinsky, Dina et al. (2016) MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia. Oncotarget 7:38974-38987
Lin, Jianhong; Zhang, Weihong; Zhao, Jian-Jun et al. (2016) A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood 128:249-52
Hunter, Zachary R; Xu, Lian; Yang, Guang et al. (2016) Transcriptome sequencing reveals a profile that corresponds to genomic variants in Waldenström macroglobulinemia. Blood 128:827-38
Ray, Arghya; Ravillah, Durgadevi; Das, Deepika S et al. (2016) A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells. Br J Haematol 174:397-409
Mullikin, Trey C; Rajkumar, S Vincent; Dispenzieri, Angela et al. (2016) Clinical characteristics and outcomes in biclonal gammopathies. Am J Hematol 91:473-5
An, Gang; Acharya, Chirag; Feng, Xiaoyan et al. (2016) Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood 128:1590-603
Tagde, Ashujit; Rajabi, Hasan; Bouillez, Audrey et al. (2016) MUC1-C drives MYC in multiple myeloma. Blood 127:2587-97
Jiang, H; Acharya, C; An, G et al. (2016) SAR650984 directly induces multiple myeloma cell death via lysosomal-associated and apoptotic pathways, which is further enhanced by pomalidomide. Leukemia 30:399-408
Gullà, Annamaria; Di Martino, Maria Teresa; Gallo Cantafio, Maria Eugenia et al. (2016) A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res 22:1222-33

Showing the most recent 10 out of 351 publications